Targeted Treatment for Advanced Non-Small Cell Lung Cancer with a MET Exon 14 Skipping Gene Change

Short Title: S1900K

Enrollment Status: Recruiting

NCT #: NCT06031688

Specialty Area: Oncology

Condition Studied: Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Age Groups: Adult; Older Adult

Phase: II

Study Information

Summary / Purpose

To find out if combining tepotinib with ramucirumab works better than tepotinib alone in treating advanced lung cancer with a MET gene change.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with advanced (stage IV) or recurrent Non-Small Cell Lung Cancer (NSCLC) with a MET exon 14 skipping mutation
Must be eligible to receive targeted therapy

What's Involved

Participation in the study will include:

Treatment with tepotinib given orally with or without ramucirumab given intravenously (IV)
CT scans, MRI, and lymphoscintigraphy to monitor response to treatment
Blood and tissue sample collection to monitor your health and treatment effects
Questionnaires

Principal Investigator

Katharine Thomas, MD

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06031688

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews